Search research articles
Contact Us
Filters
Showing results (411-420 of 456) with videos related to
Page
of 46
Sort By:
Lancet (London, England)
|
June 6, 2024
Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Hans Gelderblom, Vivek Bhadri, Silvia Stacchiotti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 23, 2022
Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma
Jason A Chesney, Antoni Ribas, Georgina V Long, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 17, 2024
Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial
Alexander Mm Eggermont, Michal Kicinski, Christian U Blank, et al.
JAMA Oncology
|
January 3, 2020
Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial
Alexander M M Eggermont, Michal Kicinski, Christian U Blank, et al.
NEJM Evidence
|
February 6, 2024
Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma
Alexander M M Eggermont, Michal Kicinski, Christian U Blank, et al.
The New England Journal of Medicine
|
June 2, 2015
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
James Larkin, Vanna Chiarion-Sileni, Rene Gonzalez, et al.
The New England Journal of Medicine
|
September 12, 2017
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Jedd D Wolchok, Vanna Chiarion-Sileni, Rene Gonzalez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 18, 2020
Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial
Alexander M M Eggermont, Christian U Blank, Mario Mandala, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 15, 2019
Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma
Alexander M M Eggermont, Christian U Blank, Mario Mandala, et al.
The New England Journal of Medicine
|
September 12, 2017
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
Jeffrey Weber, Mario Mandala, Michele Del Vecchio, et al.
Page
of 46
Search research articles
Search
Showing results (411-420 of 456) with videos related to
Sort By:
Page
of 46
Lancet (London, England)
|
June 6, 2024
Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Hans Gelderblom, Vivek Bhadri, Silvia Stacchiotti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 23, 2022
Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma
Jason A Chesney, Antoni Ribas, Georgina V Long, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 17, 2024
Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial
Alexander Mm Eggermont, Michal Kicinski, Christian U Blank, et al.
JAMA Oncology
|
January 3, 2020
Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial
Alexander M M Eggermont, Michal Kicinski, Christian U Blank, et al.
NEJM Evidence
|
February 6, 2024
Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma
Alexander M M Eggermont, Michal Kicinski, Christian U Blank, et al.
The New England Journal of Medicine
|
June 2, 2015
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
James Larkin, Vanna Chiarion-Sileni, Rene Gonzalez, et al.
The New England Journal of Medicine
|
September 12, 2017
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Jedd D Wolchok, Vanna Chiarion-Sileni, Rene Gonzalez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 18, 2020
Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial
Alexander M M Eggermont, Christian U Blank, Mario Mandala, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 15, 2019
Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma
Alexander M M Eggermont, Christian U Blank, Mario Mandala, et al.
The New England Journal of Medicine
|
September 12, 2017
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
Jeffrey Weber, Mario Mandala, Michele Del Vecchio, et al.
Page
of 46